AlphAIAlphAI — Financial news for AI agents
finanznachrichten.deOCT 81 min read$ICLR

ICON plc: ICON Schedules Third Quarter 2026 Earnings Conference Call

ICON plc (NASDAQ: ICLR) announced it will release Q3 2026 earnings after market close on Oct 27, 2026, followed by a conference call on Oct 28, 2026. The company is a leading clinical research organization with global operations. It also provided a list of risks and uncertainties that could impact its financial performance.

Original reporting
finanznachrichten.de
Published Oct 8, 2026, 12:45 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 8, 2026, 1:21 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ICLR
Neutral
high confidence
Mentioned
$ICLR
Relevance
4/10
AlphAI data visualization · based on finanznachrichten.de
Decision brief

The 30-second read

$ICLRNeutralLow
01

Why it matters

The call schedule itself is unlikely to move the stock; price action will depend on the actual earnings numbers and any guidance provided during the call.

02

Market read

The announcement is of low trading relevance; the primary catalyst will be the earnings release itself.

03

What to watch

Potential hidden guidance hints in the call invitation language could be parsed for sentiment.

Relevance 4/10Novelty 3/10Timing: pre‑market on Oct 27 2026 before earnings release

Background

ICON plc is a Dublin‑based CRO that regularly provides earnings updates. This notice simply sets the date for its upcoming Q3 2026 results.

Company-level read

Ticker impact

$ICLRNeutralHigh confidence
Context

ICON plc announced the date and time of its Q3 2026 earnings conference call and webcast.

Expected impact

minimal impact as investors await the actual earnings release.

Evidence & confidence

No quantitative information was disclosed; the news is purely informational.

Market effects

Sector

None; the announcement does not affect the broader clinical‑research sector.

Regional

None; the call is scheduled for a U.S. audience but has no immediate regional effect.

Global

Limited; only investors tracking ICON will note the timing.

Counterpoint

What could challenge this read

Some traders may view the lack of new guidance as a sign of stagnation and could short ahead of the earnings release.

Key entities

  • Company
    ICON plc

    World‑leading clinical research organization.

Read at source← All news

Related articles

JUL 29
$ICLRMedAI 9/10

ICON plc: ICON Reports Second Quarter 2026 Results

ICON plc (NASDAQ: ICLR) reported Q2 2026 results. Revenue was $2,063.5 million, up 1.4% QoQ. Adjusted EBITDA was $327.2 million (15.9% of revenue). GAAP net income was $72.6 million ($0.94 diluted EPS) and adjusted net income was $198.4 million ($2.56 adjusted EPS). Net business wins were $3,120 million, backlog $23.4 billion, and it reaffirmed 2026 guidance.

finanznachrichten.de3 min
JUL 29
$ICLRHighAI 8/10

ICON PLC (ICLR): Financial results for Q2 2026

ICON PLC (ICLR) furnished an SEC Form 6-K — earnings release. Exhibit 99.1 ICON Reports Second Quarter 2026 Results Highlights • Quarter two revenue of $2,063.5 million, an increase of 1.4% on quarter one 2026. • Quarter two adjusted EBITDA of $327.2 million or 15.9% of revenue, an increase of 3.0% on quarter one 2026. • GAAP net income for

SEC EDGAR 6-K2 min
JUL 28
$ICLRMed

ICON stock surges 7% on Anthropic AI partnership for trials By Investing.com

ICON plc (NASDAQ:ICLR) shares rose about 7.8% after the company announced a multi-year partnership with Anthropic to integrate Claude AI into its Orbis clinical trial platform. ICON said the collaboration will add four production capabilities, including site intelligence and enrollment risk detection, and will roll out Claude across roles. ICON cited enrollment delays affecting up to 80% of trials.

investing.com3 min